Earlier lung cancer diagnosis exposed major delays in curative radiotherapy access
In 2024, only 3.2% of English patients began curative radiotherapy within the 49-day target despite rapidly rising demand.
Tag
SABR
Stereotactic radiotherapy plus atezolizumab missed the AZTEC efficacy target
Neither fractionation schedule rejected the prespecified progression-free survival benchmark; durable benefit was confined to patients with oligometastatic disease.
Prostate SABR practice varied despite broad adoption across Australia and New Zealand
Most surveyed oncologists offered prostate SABR, but patient selection, target volumes, focal boosts and access to supporting technology varied.
Small gastrointestinal PRV margins limited dose increases but did not encompass pancreatic SABR motion
Two- to five-millimetre gastrointestinal margins usually limited delivered dose increases but frequently failed to encompass interfraction organ motion.
Consolidative and salvage primary-tumour SABR showed similar outcomes in stage IV NSCLC
Primary-tumour SABR before progression or at oligoprogression produced similar survival and pneumonitis rates in selected patients with stage IV NSCLC.
Posterior tumour drift threatens lung stereotactic ablative radiotherapy target coverage
In free-breathing lung stereotactic ablative radiotherapy, posterior drift exceeded the 4-millimetre margin in 15.7% of patients within 20 minutes.
Percussive ventilation enabled imaging and lung stereotactic ablative radiotherapy within one breath-hold
Three of four patients completed final imaging and lung stereotactic ablative radiotherapy within one assisted breath-hold, with only grade 1 adverse events.
K-means rapidly optimized isocenters and margins for polymetastatic stereotactic ablative radiotherapy
K-means matched hybrid optimization for margin volume while reducing median computation time from 306.9 seconds to 0.19 seconds.